Skip to main content
SpringerLink
Log in
Book cover

Preventive Dermatology pp 63–70Cite as

Prevention of Drug Reactions and Allergies in Dermatology

  • Chapter
  • First Online:

  • 1203 Accesses

Abstract

Adverse drug reactions are defined as noxious or unintended responses to a drug used in standard doses for the purpose of prophylaxis, diagnosis, or treatment.8 Many side effects to a medication are recognized and accepted as part of the risk/benefit evaluation in determining whether or not it is indicated in a particular patient. For example, diarrhea is a recognized adverse drug reaction associated with the use of erythromycin in 7% of patients.33 However, it is not an intended response when the drug is used to cure an infection, yet we recognize it as a frequent consequence of oral erythromycin use and are willing to accept this risk in order to achieve the benefit.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ammoury A, Michaud S, et al Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol. 2008;144(1):92–96

    Article  PubMed  CAS  Google Scholar 

  2. Atkin PA, Veitch PC, et al The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging. 1999;14(2):141–152

    Article  PubMed  CAS  Google Scholar 

  3. Baldi BG, Santana AN, et al Pulmonary and cutaneous nocardiosis in a patient treated with corticosteroids. J Bras Pneumol. 2006;32(6):592–595

    Article  PubMed  Google Scholar 

  4. Bates DW, Leape LL, et al Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8(6):289–294

    Article  PubMed  CAS  Google Scholar 

  5. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765–770

    PubMed  CAS  Google Scholar 

  6. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002;3(1):47–58

    Article  PubMed  Google Scholar 

  7. Chan AT, Cleeve V, et al Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002;78(915):47–48

    Article  PubMed  CAS  Google Scholar 

  8. Cousins DD. Medication Use: A Systems Approach to Reducing Errors. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 1998

    Google Scholar 

  9. Cullen DJ, Bates DW, et al The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv. 1995;21(10):541–548

    PubMed  CAS  Google Scholar 

  10. Deng A, Harvey V, et al Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142(2):198–202

    Article  PubMed  Google Scholar 

  11. Devos SA, Van Den Bossche N, et al Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology. 2003;206(4):388–390

    Article  PubMed  CAS  Google Scholar 

  12. Fardet L, Flahault A, et al Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157(1):142–148

    Article  PubMed  CAS  Google Scholar 

  13. Fiszenson-Albala F, Auzerie V, et al A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149(5):1018–1022

    Article  PubMed  CAS  Google Scholar 

  14. Gaig P, Garcia-Ortega P, et al Drug neosensitization during anticonvulsant hypersensitivity syndrome. J Investig Allergol Clin Immunol. 2006;16(5):321–326

    PubMed  CAS  Google Scholar 

  15. Garcia-Doval I, LeCleach L, et al Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–327

    Article  PubMed  CAS  Google Scholar 

  16. Hengge UR, Ruzicka T, et al Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15; quiz 16–18

    Article  PubMed  Google Scholar 

  17. Hilas O, Charneski L. Lamotrigine-induced Stevens-Johnson syndrome. Am J Health Syst Pharm. 2007;64(3): 273–275

    Article  PubMed  CAS  Google Scholar 

  18. Hunziker T, Kunzi UP, et al Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997;52(4):388–393

    Article  PubMed  CAS  Google Scholar 

  19. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995; 155(18):1949–1956

    Article  PubMed  CAS  Google Scholar 

  20. Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol Clin. 2007; 25(2):245–253, viii

    Article  PubMed  CAS  Google Scholar 

  21. Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr. 2006;6(2):33–37

    Article  PubMed  Google Scholar 

  22. Mockenhaupt M, Messenheimer J, et al Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134–1138

    Article  PubMed  CAS  Google Scholar 

  23. Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy. 2007;27(7):1020–1028

    Article  PubMed  CAS  Google Scholar 

  24. Naldi L, Conforti A, et al Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol. 1999;48(6):839–846

    Article  PubMed  CAS  Google Scholar 

  25. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions – new concepts. Clin Exp Allergy. 2007;37(7):989–999

    Article  PubMed  CAS  Google Scholar 

  26. Rademaker M, Oakley A, Duffill MB. Cutaneous adverse drug reactions in a hospital setting. N Z Med J. 1995; 108(999):165–166

    PubMed  CAS  Google Scholar 

  27. Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol. 2003; 24(7):376–379

    Article  PubMed  CAS  Google Scholar 

  28. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68(9):1781–1790

    PubMed  Google Scholar 

  29. Roychowdhury S, Svensson CK. Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. Aaps J. 2005;7(4):E834–E846

    Article  PubMed  CAS  Google Scholar 

  30. Rzany B, Correia O, et al Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999;353(9171):2190–2194

    Article  PubMed  CAS  Google Scholar 

  31. Schoepe S, Schacke H, et al Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–420

    Article  PubMed  CAS  Google Scholar 

  32. Segal A, Doherty K, et al Cutaneous reactions to drugs in children. Pediatrics. 2007;120(4):e1082–e1096

    Article  PubMed  Google Scholar 

  33. Semla TP, Beizer JL, et al Geriatric Dosage Handbook. Hudson, OH: Lexi-Comp; 2006.

    Google Scholar 

  34. Shipley D, Ormerod AD. Drug-induced urticaria. Recognition and treatment. Am J Clin Dermatol. 2001;2(3): 151–158

    Article  PubMed  CAS  Google Scholar 

  35. Svensson C, EW C, et al Cutaneous drug reactions. Pharmacol Rev. 2000;53(3):357–379

    Google Scholar 

  36. U.S. Food and Drug Administration, (March 10, 2005). FDA Public Health Advisory Elidel (Pimecrolimus) Cream and Protopic (Tacrolimus) Ointment. Retrieved 21 December 2009, from http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051760.htm

  37. U.S. Food and Drug Administration, (December 12, 2007). Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions - Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). Retrieved 21 December 2009, from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm

  38. van der Linden PD, van der Lei J, et al Skin reactions to antibacterial agents in general practice. J Clin Epidemiol. 1998;51(8):703–708

    Article  PubMed  Google Scholar 

  39. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007; 298(11):1312–1322

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Lisa C. Hutchison

Authors
  1. Lisa C. Hutchison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oumitana Kajkenova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa C. Hutchison .

Editor information

Editors and Affiliations

  1. West Waters Ave. 7902, Tampa, 33615, USA

    Robert Norman

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London

About this chapter

Cite this chapter

Hutchison, L.C., Kajkenova, O. (2011). Prevention of Drug Reactions and Allergies in Dermatology. In: Norman, R. (eds) Preventive Dermatology. Springer, London. https://doi.org/10.1007/978-1-84996-021-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-84996-021-2_7

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-020-5

  • Online ISBN: 978-1-84996-021-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation